Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180294 · ClinicalTrials.gov registry record · Phase 2
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
A Phase 2 study of Breast Carcinoma and Ovarian Carcinoma, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT03180294 is a Phase 2 study of Breast Carcinoma and Ovarian Carcinoma that has completed, run by NRG Oncology. The registered enrollment target is 230 participants, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 1 state.
The verdict
NCT03180294, a Phase 2 study of Breast Carcinoma and Ovarian Carcinoma, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work by boosting sexual desire, energy, or motivation without causing intolerable or undesirable side effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bupropion 150 mg XL
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Fremont - Fremont
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente - Harbor City - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente-Cadillac - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente-Ontario - Ontario
- Kaiser Permanente - Panorama City - Panorama City
- Kaiser Permanente-Redwood City - Redwood City
- Kaiser Permanente-Richmond - Richmond
- Kaiser Permanente-Riverside - Riverside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180294
The ClinicalTrials.gov registry entry for NCT03180294 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (70% lower). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03180294 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03180294 about?
NCT03180294 is a clinical study titled "Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer". This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work by boosting sexual desire, energy, or motivation without causing intolerable or undesirable side effects.
What is the current status of trial NCT03180294?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2017-05-31. Estimated completion is 2021-02-22.
What conditions does trial NCT03180294 study?
This clinical trial studies the following conditions: Breast Carcinoma, Ovarian Carcinoma, Cervical Carcinoma, Postmenopausal, Vulvar Carcinoma.
What interventions are being tested in trial NCT03180294?
The interventions under investigation include: Placebo (DRUG), Bupropion 150 mg XL (DRUG).
Who is sponsoring clinical trial NCT03180294?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03180294 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RECRUITING · Phase 2
-
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
RECRUITING · Phase 2
-
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
RECRUITING · Phase 2
-
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.